NCT07209410View on ClinicalTrials.gov

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 15, 2026

Study Completion Date

June 1, 2027

Conditions
Glaucoma
Interventions
DRUG

Brimonidine Tartrate Ophthalmic 0.025%

Lumify is an approved eye drop to minimize ocular hyperemia.

Trial Locations (1)

64111

Vision Source, Kansas City

All Listed Sponsors
lead

Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

OTHER